Boston Scientific Analyst Slashes Price Target On Disappointing 2026 Outlook

Boston Scientific Corporation +1.32%

Boston Scientific Corporation

BSX

62.82

+1.32%

Although Boston Scientific Corp (NYSE:BSX) reported fourth-quarter revenue and earnings ahead of consensus estimates, it announced disappointing 2026 guidance, according to Needham.

The Boston Scientific Analyst: Analyst Mike Matson maintained a Buy rating, but slashed the price target from $121 to $97.

The Boston Scientific Thesis: The company reported revenue of $5.286 billion and adjusted earnings of 80 cents per share, topping consensus estimates of $5.280 billion and 78 cents per share, respectively, Matson said in the note.

Check out other analyst stock ratings.

Boston Scientific's organic growth slowed to 12.7%, from 15.3% in the third quarter "as FARAPULSE growth slowed due to increasing competition and slowing PFA adoption," he added.

"MedSurg growth slowed as improved Neuromodulation growth was more than offset by slower Endoscopy and Urology growth," the analyst wrote.

Management guided to 2026 revenue growth of 10.5%-11.5%, implying a revenue range of $22.182-$22.383 billion, with the midpoint falling short of consensus of $22.370 billion, while earnings guidance came in at $3.43-$3.49 per share, versus consensus of $3.47 per share, he further stated.

BSX Price Action: Shares of Boston Scientific had risen by 2.08% to $77.07 at the time of publication on Thursday.

Image: Shutterstock

This page is machine-translated. Sahm tries to improve but does not guarantee the accuracy and reliability of the translation, and will not be liable for any loss or damage caused by any inaccuracy or omission of the translation. *Disclaimer: The above content only represents the author's personal position and opinion and does not represent any position of Sahm Capital Financial Company and Sahm cannot confirm the authenticity, accuracy, and originality of the above content. Investors should consider the risks of investment products in light of their circumstances before making any investment decisions. When necessary, please consult a professional investment advisor. Sahm does not provide any investment advice, nor does it make any commitments and guarantees.